Latest Research
All publications from the Cancer3.AI database, newest first.
Robot-Assisted Partial Nephrectomy via a Retroperitoneal Approach With Selective Arterial Clamping Guided by Blood Flow Analysis in a Horseshoe Kidney: A Case Report.
Fujita T, et al
Surgeons in Japan have reported a successful case of robot-assisted partial kidney removal in a patient with a horseshoe kidney, a rare congenital condition where both kidneys are fused together. A 43-year-old woman was found to have a small tumor in her horseshoe kidney, and advanced 3D imaging software was used to map the blood supply to the tumor before surgery. This analysis revealed that the tumor was fed by a single artery, allowing surgeons to clamp only that vessel rather than cutting off blood flow to the entire kidney, thereby protecting kidney function. Because the fused kidney's unusual position beneath the liver made standard surgical access impossible, the team devised a customized entry point and combined laparoscopic and robotic techniques to navigate the limited space. The operation was completed with minimal blood loss and full preservation of renal function, demonstrating that careful preoperative planning can overcome the complex anatomy of horseshoe kidneys. This case offers a valuable roadmap for urologists facing similarly challenging anatomical variants in nephron-sparing surgery.
IJU case reports
Source →Fabrication of methotrexate conjugated multi-walled carbon nanotubes for the evaluation of cytotoxic potential at biochemical and molecular level modulating BAX, BCL-2 and telomerase expression.
Tiwari H, et al
Researchers developed a novel nanotherapeutic system by covalently conjugating the widely used anticancer drug methotrexate (MTX) to multi-walled carbon nanotubes (MWCNTs), aiming to overcome the drug's known limitations in solubility and biocompatibility. The MTX-MWCNT conjugate was tested against three cancer cell lines—MCF-7 (hormone-positive breast cancer), MDA-MB-231 (triple-negative breast cancer), and HeLa (cervical cancer)—where it demonstrated potent, dose-dependent reduction in cancer cell viability while showing minimal toxicity toward normal kidney cells and red blood cells. Molecular analyses revealed that the conjugate promoted apoptosis by upregulating the pro-apoptotic BAX gene and downregulating the anti-apoptotic BCL-2 gene, with ELISA further confirming reduced telomerase protein expression, a marker associated with cancer cell immortality. Additionally, an ex vivo chick chorioallantoic membrane assay showed the conjugate significantly inhibited the formation of new blood vessels, suggesting anti-angiogenic properties that could starve tumors of their nutrient supply. These findings position MTX-MWCNTs as a promising, safer alternative to conventional methotrexate therapy, with potential benefits for patients suffering from breast and cervical cancers who currently experience significant drug side effects.
RSC advances
Source →Use of Single-Cell Data and scPagwas Analysis to Identify T Cell Subsets and Construct a Prognostic Model for Clear Cell Renal Cell Carcinoma.
Yi X, et al
Researchers conducted a comprehensive multi-omics study to develop a new prognostic model for clear cell renal cell carcinoma (KIRC), the most common and aggressive form of kidney cancer, which accounts for up to 84% of all renal cell carcinoma cases. By integrating single-cell RNA sequencing, genome-wide association study (GWAS) data, and tumor genomics datasets using the scPagwas algorithm, the team identified T cell subsets as key immune players in the KIRC tumor microenvironment. Through a combination of weighted gene co-expression network analysis and machine learning algorithms including XGBoost and LightGBM, the researchers narrowed down 86 candidate genes to a seven-gene risk model that accurately stratified patients into low- and high-risk survival groups. The gene DOCK8 emerged as a particularly promising biomarker, and molecular docking analysis identified five existing drugs — finasteride, nocodazole, palonosetron, pifithrin alpha, and topiramate — as potential therapeutic agents targeting DOCK8. These findings offer clinicians a new tool for predicting patient outcomes in KIRC and open new avenues for drug repurposing and targeted therapy development.
Human mutation
Source →Biomaterial-Driven Integrated Therapy for Renal Cell Carcinoma: Renal Cancer Control and Kidney Injury Repair.
Song J, et al
A new review published in Research (Washington, D.C.) examines how advanced biomaterials can transform the treatment of renal cell carcinoma (RCC), the most common urologic malignancy, which continues to challenge clinicians due to postoperative recurrence, drug resistance, metastasis, and therapy-induced kidney damage. The authors conducted a comprehensive analysis of the current landscape of biomedical materials designed specifically for RCC, highlighting their advantages over conventional drugs, including superior tumor targeting, improved safety profiles, and the ability to produce synergistic therapeutic effects. A key contribution of this review is the proposal of an integrated strategy that simultaneously fights the tumor and protects remaining kidney tissue from treatment-related injury and fibrosis, addressing two problems that have historically been treated separately. The authors introduce an analytical framework built around the fundamental contradictions in biomaterial design, such as functional conflicts between drug delivery and tissue protection, stimuli-responsive activation, and metabolic safety considerations. This dual-focus approach offers clinicians and researchers a new conceptual roadmap for developing next-generation therapies that could meaningfully improve outcomes and quality of life for RCC patients.
Research (Washington, D.C.)
Source →A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.
Silver RT, et al
This review article examines the growing body of evidence supporting recombinant interferon-alpha (rIFNα) as the preferred first-line treatment for polycythemia vera (PV), a chronic blood cancer caused by an overproduction of blood cells. Over 35 years of research, including landmark trials such as PROUD-CONTI and Low-PV, have demonstrated that ropeginterferon alpha-2b (ropegIFN) outperforms both the traditional cytoreductive drug hydroxyurea and phlebotomy alone in controlling disease and achieving molecular remission of the JAK2V617F mutation. These findings prompted regulatory approvals from both the European Medicines Agency in 2019 and the U.S. Food and Drug Administration in 2021, positioning ropegIFN as a validated option for both low-risk and high-risk PV patients. The authors argue for a paradigm shift in clinical practice, recommending that rIFNα be initiated early in all PV patients unless contraindicated, since even low-risk patients face a two-to-threefold increased risk of thrombosis compared to the general population. This recommendation is further supported by evidence suggesting that phlebotomy alone may contribute to disease progression toward myelofibrosis, a serious and debilitating complication of PV.
Leukemia
Source →